Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Apolipoprotein A-I (ApoA-I) amyloidosis is a rare protein misfolding disease where fibrils of the N-terminal domain of the protein accumulate in several organs, leading to their failure. Although ApoA-I amyloidosis is systemic, the different amyloidogenic variants show a preferential tissue accumulation that appears to correlate with the location of the mutation in the protein sequence and with the local extracellular microenvironment. However, the factors leading to cell/tissues damage, as well as the mechanisms behind the observed organ specificity are mostly unknown. Therefore, we investigated the impact of ApoA-I variants on cell physiology and the mechanisms driving the observed tissue specificity. We focused on four ApoA-I amyloidogenic variants and analyzed their cytotoxicity as well as their ability to alter redox homeostasis in cell lines from different tissues (liver, kidney, heart, skin). Moreover, variant-specific interactions with extracellular matrix (ECM) components were measured by synchrotron radiation circular dichroism and enzyme-linked immunosorbent assay. Data indicated that ApoA-I variants exerted a cytotoxic effect in a time and cell-type-specific manner that seems to be due to protein accumulation in lysosomes. Interestingly, the ApoA-I variants exhibited specific preferential binding to the ECM components, reflecting their tissue accumulation pattern . While the binding did not to appear to affect protein conformations in solution, extended incubation of the amyloidogenic variants in the presence of different ECM components resulted in different aggregation propensity and aggregation patterns.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820410PMC
http://dx.doi.org/10.3390/ijms24010318DOI Listing

Publication Analysis

Top Keywords

apoa-i variants
16
amyloidogenic variants
12
ecm components
12
extracellular matrix
8
apoa-i amyloidosis
8
tissue accumulation
8
apoa-i
7
variants
7
protein
5
apparent organ-specificity
4

Similar Publications

An increasing body of research indicates an association between lipid-lowering medications and sensorineural hearing loss (SNHL), although there is still controversy. Therefore, the aim of this study is to investigate the genetic correlation between different lipid-lowering therapeutic gene targets and SNHL. The genetic association between lipids, lipid-lowering drug target genes, and SNHL was analyzed using a 2-sample Mendelian randomization approach.

View Article and Find Full Text PDF

Background: The coronavirus disease of 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2, has affected millions of people worldwide. The omicron variant is currently the predominant strain circulating worldwide. Serum apolipoprotein A1 (ApoA1) is linked to endothelial cell injury and serves as a valuable biomarker for monitoring the progression of inflammation in infected individuals.

View Article and Find Full Text PDF

Apolipoprotein A-I binding protein (AIBP) interacts with both apolipoprotein A-I and high-density lipoprotein. It modulates lipid raft-related signaling pathways and affects mitochondrial function, oxidative stress, and inflammatory responses, thereby playing an important role in atherosclerosis, neuroinflammation, and neurological disorders. The role of AIBP in cardiovascular diseases has been intensively studied.

View Article and Find Full Text PDF

Purpose: To identify the connections between lipid biomarkers and the anti-VEGF therapy response in patients with neovascular age-related macular degeneration (nAMD).

Design: A bidirectional and multivariable Mendelian randomization study.

Participants: The summary statistics for anti-VEGF nAMD treatment response included a total of 128 responders, 51 nonresponders, and 6 908 005 genetic variants available for analysis.

View Article and Find Full Text PDF

An unusual phenotype of hereditary AApoAI amyloidosis caused by a novel Asp20Tyr substitution is linked to pH-dependent aggregation of apolipoprotein A-I.

Biochim Biophys Acta Mol Basis Dis

June 2025

Department of Pharmacology, Physiology & Biophysics, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA. Electronic address:

Apolipoprotein A-I (apoA-I) plays beneficial roles as the major structural and functional protein on plasma high-density lipoproteins (HDL). However, APOA1 gene mutations can cause protein misfolding and pathologic amyloid deposition in various organs in human hereditary AApoAI amyloidosis, a potentially lethal systemic disease. We report esophageal and duodenal AApoAI amyloidosis in a 56-year-old patient with Barrett's esophagus, a condition involving chronic acid reflux.

View Article and Find Full Text PDF